Nazim Benzerdjeb

Dr. Nazim Benzerdjeb


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LBLaurence Bauwens
Laurence Bauwens
ABAline Baltres
Aline Baltres
DFDanny-Joe Fiani
Danny-Joe Fiani
PZPhilippe Zrounba
Philippe Zrounba
GBGuillaume Buiret
Guillaume Buiret
VGVincent Grégoire
Vincent Grégoire

9 February 2021 in Histopathology
Verified
Journal Article
Closed access
PDF file
NBNazim Benzerdjeb
Nazim Benzerdjeb
JTJuliet Tantot
Juliet Tantot
CBChristophe Blanchet
Christophe Blanchet
PPPierre Philouze
Pierre Philouze
YMYahia Mekki
Yahia Mekki
MDMojgan Devouassoux‐Shisheboran
Mojgan Devouassoux‐Shisheboran

7 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
NBNazim Benzerdjeb
Nazim Benzerdjeb
HSHenri Sevestre
Henri Sevestre
AAAhmed Ahidouch
Ahmed Ahidouch
HOHalima Ouadid-Ahidouch
Halima Ouadid-Ahidouch
Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma

2 May 2016 in Cancer Cytopathology
Verified
Journal Article
Open access
PDF file
NBNazim Benzerdjeb
Nazim Benzerdjeb
CGChristian GARBAR
Christian GARBAR
PCPhilippe Camparo
Philippe Camparo
HSHenri Sevestre
Henri Sevestre
BACKGROUND: The liquid‐based cytology Papanicolaou (Pap) test has gradually replaced the conventional Pap test, as it seems to be more efficient, in part because it uses computer assistance. However, Pap test diagnoses are still subjective and are cost‐consuming or time‐consuming. The authors describe a new digital holographic microscopy instrument and accompanying software. This technology provides an instantaneous, 3‐dimensional image reconstruction of cells directly from the uterine cervical sample vial.METHODS: Analyses were performed using the proprietary digital holographic microscopy (DHM) instrument, computer, and software. Residual materials from 3 randomly chosen laboratories were analyzed and subjected to DHM, and the sensitivity and specificity of DHM were calculated for the detection neoplasia.RESULTS: In 41 specimens that yielded normal Pap test results, 1333 cells were analyzed using DHM; and, in 30 specimens that yielded abnormal Pap test results, 494 cells were analyzed using DHM. Available histologic correlation was as follows: 4 histologic samples were diagnosed as grade 1 cervical intraepithelial neoplasia (corresponding to 2 cytologic diagnoses of low‐grade squamous intraepithelial lesion and 2 cytologic diagnoses of atypical squamous cells of undetermined significance), 4 histologic samples were diagnosed as grade 3 cervical intraepithelial neoplasia (corresponding to 2 cytologic diagnoses of low‐grade squamous intraepithelial lesion and 2 cytologic diagnosis of atypical squamous cells, cannot rule out high‐grade squamous intraepithelial lesion), and 11 lesions were diagnosed as benign. Receiver operating characteristic curve analysis indicated that the best criteria were the nuclear‐to‐cytoplasmic ratio (area under the curve, 0.88; 95% confidence interval, 0.68‐1.00) and the greatest nuclear dimension (area under the curve, 0.85; 95% confidence interval, 0.66‐1.00).CONCLUSIONS: This preliminary study demonstrated for the first time that the DHM technique is suitable for the processing of gynecologic cervical samples. Nevertheless, DHM criteria and parameters could be better defined. Hopefully, holographic analysis will be performed automatically and will provide an instantaneous, cost‐effective diagnosis from a closed vial with the preservation of all cellular material. Cancer Cytopathol 2016;124:573‐80. © 2016 American Cancer Society.

14 February 2020 in Histopathology
Verified
Journal Article
Closed access
PDF file
NBNazim Benzerdjeb
Nazim Benzerdjeb
EDEmeline Durieux
Emeline Durieux
JTJuliet Tantot
Juliet Tantot
SISylvie Isaac
Sylvie Isaac
JFJuliette Fontaine
Juliette Fontaine
NBNaoual Bakrin
Naoual Bakrin

12 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HDHiba Abou Daya
Hiba Abou Daya
SKSana Kouba
Sana Kouba
HHHAKIM OULED HADDOU
HAKIM OULED HADDOU
NBNazim Benzerdjeb
Nazim Benzerdjeb
MTMarie-Sophie Telliez
Marie-Sophie Telliez
HOHalima Ouadid-Ahidouch
Halima Ouadid-Ahidouch
The development of the resistance to platinum salts is a major obstacle in the treatment of non-small cell lung cancer (NSCLC). Among the reasons underlying this resistance is the enrichment of cancer stem cells (CSCs) populations. Several studies have reported the involvement of calcium channels in chemoresistance. The Orai3 channel is overexpressed and constitutes a predictive marker of metastasis in NSCLC tumors. Here, we investigated its role in CSCs populations induced by Cisplatin (CDDP) in two NSCLC cell lines. We found that CDDP treatment increased Orai3 expression, but not Orai1 or STIM1 expression, as well as an enhancement of CSCs markers. Moreover, Orai3 silencing or the reduction of extracellular calcium concentration sensitized the cells to CDDP and led to a reduction in the expression of Nanog and SOX-2. Orai3 contributed to SOCE (Store-operated Calcium entry) in both CDDP-treated and CD133+ subpopulation cells that overexpress Nanog and SOX-2. Interestingly, the ectopic overexpression of Orai3, in the two NSCLC cell lines, lead to an increase of SOCE and expression of CSCs markers. Furthermore, CD133+ cells were unable to overexpress neither Nanog nor SOX-2 when incubated with PI3K inhibitor. Finally, Orai3 silencing reduced Akt phosphorylation. Our work reveals a link between Orai3, CSCs and resistance to CDDP in NSCLC cells.